YOLFTbeta
Samsung Pharm

Samsung Pharm

001360 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

1,328.00KRW+19.00 (+1.45%)

Price History

Full chart

Market Stats

Previous Close1,309.00
Open1,310.00
Day Range1,230.00 – 1,363.00
52-Week Range1,140.00 – 2,320.00
Volume387.05K
Market Cap122.07B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.74
50-Day Avg1,305.64
200-Day Avg1,591.67

About

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamins, antibiotics, and others. The company also provides medicines for the digestive system, medicines for liver disorders, medicines for the circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, cold medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOSung Tag Jung
  • Employees0
  • Headquarters10, Yakgongdan 4-gil, Hwaseong-si, South Korea, 18622, Korea
  • Websitehttps://www.sspharm.co.kr

Leadership

  • Sung Tag JungCEO & Chairman · b. 1977
  • HwaYeong ParkInternal Director & VP

Financials

Income Statement

Currency: KRW2012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue47.29B30.29B42.16B48.22B41.92B46.48B44.57B48.27B54.90B51.83B51.96B44.29B46.07B
Growth (%)--35.95%+39.21%+14.37%-13.07%+10.89%-4.12%+8.31%+13.74%-5.59%+0.24%-14.75%+4.02%
Cost of Revenue28.15B21.82B30.91B40.61B36.84B37.89B35.17B37.82B45.62B27.21B28.98B24.52B32.09B
Gross Profit19.14B8.47B11.26B7.61B5.08B8.59B9.40B10.45B9.28B24.62B22.97B19.77B13.98B
Gross Margin40.47%27.96%26.70%15.78%12.12%18.48%21.09%21.65%16.91%47.50%44.22%44.64%30.34%
Operating Expense18.60B28.29B13.13B17.20B11.96B13.37B14.62B20.25B27.42B38.58B41.01B34.60B32.05B
Operating Income541.60M-19.82B-1.87B-9.59B-6.88B-4.78B-5.22B-9.80B-18.14B-13.96B-18.04B-14.83B-18.07B
Operating Margin1.15%-65.44%-4.44%-19.88%-16.41%-10.29%-11.72%-20.30%-33.04%-26.94%-34.72%-33.48%-39.22%
EBITDA-----4.46B3.10B12.01B-33.59B-36.57B-21.97B-21.69B-11.74B14.18B
EBITDA Margin-----10.64%6.68%26.95%-69.59%-66.60%-42.40%-41.74%-26.50%30.78%
Net Income-3.13B-23.75B-994.38M-21.62B-7.54B-2.08B6.89B-39.88B-40.28B-25.09B-24.81B-14.09B11.55B
Net Income Margin-6.62%-78.41%-2.36%-44.83%-17.99%-4.47%15.45%-82.61%-73.36%-48.41%-47.76%-31.81%25.06%
R&D5.83M5.83M296.67M926.54M938.79M377.51M90.93M663.58M650.54M327.02M2.28B1.29B1.99B
R&D as % of Total Revenue0.01%0.02%0.70%1.92%2.24%0.81%0.20%1.37%1.18%0.63%4.39%2.91%4.33%
Interest Expense000001.36B707.58M2.09B506.88M111.09M73.37M231.04M1.20B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%2.92%1.59%4.32%0.92%0.21%0.14%0.52%2.59%

Balance Sheet

Currency: KRW2012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets103.02B57.41B130.22B138.28B154.19B160.65B168.53B178.73B145.46B117.91B93.48B128.45B167.44B
Total Liabilities68.31B34.12B83.98B55.91B60.33B28.98B25.70B56.81B18.19B15.32B15.89B22.60B46.39B
Total Equity34.71B23.29B46.24B82.38B93.87B131.66B142.83B121.92B127.27B102.59B77.58B105.86B121.04B
Cash8.27B3.12B19.59B5.39B2.93B3.15B5.05B26.44B26.10B35.99B4.28B7.39B11.17B
Net Debt----42.44B15.31B7.43B1.48B----6.05B

Cash Flow

Currency: KRW2012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.13B-13.58B-4.20B-9.94B5.15B-6.52B-2.43B-2.55B-7.16B-1.91B-27.66B-17.30B-10.05B
Investing Cash Flow-3.56B1.45B-51.51B-28.34B-22.26B-6.60B-------
Financing Cash Flow22.62B14.93B71.28B24.08B19.41B13.34B-------
Capital Expenditure2.45B2.09B11.86B33.24B6.11B2.61B13.88B7.15B4.07B3.03B12.78B380.73M12.76B
Free Cash Flow-----847.92M-10.21B-16.32B-9.71B-11.23B-4.95B-40.44B-17.68B-22.81B
FCF to OCF-----16.46%156.63%670.22%380.21%156.76%258.54%146.21%102.20%226.99%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2011Dec 31, 2012Jun 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 19, 2021May 14, 2021Aug 13, 2021Nov 15, 2021Mar 14, 2022May 16, 2022Aug 12, 2022Nov 14, 2022Mar 7, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 28, 2024May 16, 2024Aug 14, 2024Nov 12, 2024Feb 10, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Dec 31, 2025May 13, 2026Jun 30, 2026
EPS Estimate-------------------------------------------------------------
EPS Actual45.15-19.9064.3544.6737.1725.4318.33-79.46-327.495.76-1199.39-48.23-104.91-89.64-654.976.74138.60-129.38-53.40-64.43-90.86-111.41-235.16-49.95-39.25-52.87-14.570.2631.4211.13-74.8980.62-2.92-97.71122.65-190.51-108.8716.64-339.42-218.35-93.32-99.95-198.27-22.35-128.51-56.86-166.14-41.82-53.64-93.01-163.48-61.35-109.18194.72-184.16395.75675.44-320.55-627.9784.02-601.84
Surprise-------------------------------------------------------------
Timing------------------------------------------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap122.07B
Enterprise Value132.06B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales2.76
Price / Book1.70
Revenue (TTM)44.29B
Gross Profit (TTM)44.29B
EBITDA-4.67B
Profit Margin28.70%
Operating Margin-14.42%
Return on Equity-4.40%
Return on Assets-3.34%
Shares Outstanding94.12M
Shares Float52.43M
Beta0.74
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

19971×
85.35Jan 3, 1997
19961×
128.02Jan 3, 1996

Stock Splits

  • May 2, 2018551:504
  • Jul 18, 2016702:655